WO2004010996A1 - Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose - Google Patents

Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose Download PDF

Info

Publication number
WO2004010996A1
WO2004010996A1 PCT/JP2002/007679 JP0207679W WO2004010996A1 WO 2004010996 A1 WO2004010996 A1 WO 2004010996A1 JP 0207679 W JP0207679 W JP 0207679W WO 2004010996 A1 WO2004010996 A1 WO 2004010996A1
Authority
WO
WIPO (PCT)
Prior art keywords
naphthalenyl
oxy
group
benzoxazolyl
acid
Prior art date
Application number
PCT/JP2002/007679
Other languages
English (en)
Japanese (ja)
Inventor
Kiyoshi Nakatogawa
Masamichi Takagi
Makoto Akashima
Noriaki Ohishi
Akiko Ohshima
Original Assignee
Shizuoka Coffein Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shizuoka Coffein Co., Ltd. filed Critical Shizuoka Coffein Co., Ltd.
Priority to PCT/JP2002/007679 priority Critical patent/WO2004010996A1/fr
Priority to AU2002368133A priority patent/AU2002368133A1/en
Priority to JP2004524089A priority patent/JP4334476B2/ja
Publication of WO2004010996A1 publication Critical patent/WO2004010996A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Abstract

L'invention concerne un dérivé 1,3-azole représenté par la formule (1). Ce dérivé favorise l'accélération de l'activité d'agrégation plaquettaire et l'activité inhibitrice de PAI-1 et peut être utilisé en tant qu'agent antithrombotique ou thrombolytique, et administré par voie orale.
PCT/JP2002/007679 2002-07-29 2002-07-29 Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose WO2004010996A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/JP2002/007679 WO2004010996A1 (fr) 2002-07-29 2002-07-29 Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose
AU2002368133A AU2002368133A1 (en) 2002-07-29 2002-07-29 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
JP2004524089A JP4334476B2 (ja) 2002-07-29 2002-07-29 １，３アゾール誘導体及び同誘導体を含む血栓症治療のための医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2002/007679 WO2004010996A1 (fr) 2002-07-29 2002-07-29 Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose

Publications (1)

Publication Number Publication Date
WO2004010996A1 true WO2004010996A1 (fr) 2004-02-05

Family

ID=30795875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007679 WO2004010996A1 (fr) 2002-07-29 2002-07-29 Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose

Country Status (3)

Country Link
JP (1) JP4334476B2 (fr)
AU (1) AU2002368133A1 (fr)
WO (1) WO2004010996A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023865A1 (fr) * 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
WO2007111136A1 (fr) * 2006-03-28 2007-10-04 Adeka Corporation Composition de resine epoxy durcissable
JP2007530459A (ja) * 2004-03-26 2007-11-01 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2007138705A1 (fr) 2006-06-01 2007-12-06 Japan As Represented By Director General Of Agency Of National Cancer Center Suppresseur de tumeurs
JP2007537253A (ja) * 2004-05-12 2007-12-20 アボット・ラボラトリーズ ３環式および２環式ヘテロアリールヒスタミン３受容体リガンド
US8323805B2 (en) 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
US8354668B2 (en) 2009-06-29 2013-01-15 Nitto Denko Corporation Emissive triaryls
US8426040B2 (en) 2010-12-22 2013-04-23 Nitto Denko Corporation Compounds for use in light-emitting devices
US8927121B2 (en) 2009-06-29 2015-01-06 Nitto Denko Corporation Emissive aryl-heteroaryl compounds
US8933243B2 (en) 2011-06-22 2015-01-13 Nitto Denko Corporation Polyphenylene host compounds
CN105392777A (zh) * 2013-06-27 2016-03-09 株式会社Lg生命科学 作为gpr120激动剂的联芳基衍生物
CN109456274A (zh) * 2018-12-07 2019-03-12 广东药科大学 苯并咪唑类衍生物、其制备方法及其作为药物的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307798B1 (fr) 2015-06-12 2020-08-05 Transitions Optical, Inc. Composés d'alignement

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947582A (en) * 1973-08-16 1976-03-30 Merck & Co., Inc. Phenylacetic acid compounds in treating abnormal platelet aggregation
EP0209707A2 (fr) * 1985-06-21 1987-01-28 Dr. Karl Thomae GmbH Aryl-2-imidazoles, compositions pharmaceutiques contenant ces composés et procédé pour leur préparation
EP0419210A1 (fr) * 1989-09-22 1991-03-27 Pfizer Inc. Composés de benzimidazole et leur utilisation
US5021443A (en) * 1990-02-16 1991-06-04 Laboratoires Upsa Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
WO1993005773A1 (fr) * 1991-09-24 1993-04-01 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Inhibition therapeutique de l'agregation plaquettaire par des complexes nucleophiles-oxyde nitrique et leurs derives
WO1999026933A1 (fr) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Derives d'amidinoaryle substitue et leur utilisation comme anticoagulants
WO1999026932A1 (fr) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Derives heterocycliques substitues par un groupe amidino et leur utilisation en tant qu'anticoagulants
WO1999040072A1 (fr) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques
WO2000001704A2 (fr) * 1998-07-04 2000-01-13 Boehringer Ingelheim Pharma Kg Benzimidazoles, leur preparation et leur utilisation comme medicaments
WO2000035886A2 (fr) * 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. Inhibiteurs de proteases
WO2001047572A2 (fr) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Dispositif et constituant actif destines a inhiber la formation de thrombus-matrice cellulaire inflammatoire

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947582A (en) * 1973-08-16 1976-03-30 Merck & Co., Inc. Phenylacetic acid compounds in treating abnormal platelet aggregation
EP0209707A2 (fr) * 1985-06-21 1987-01-28 Dr. Karl Thomae GmbH Aryl-2-imidazoles, compositions pharmaceutiques contenant ces composés et procédé pour leur préparation
EP0419210A1 (fr) * 1989-09-22 1991-03-27 Pfizer Inc. Composés de benzimidazole et leur utilisation
US5021443A (en) * 1990-02-16 1991-06-04 Laboratoires Upsa Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
US5124336A (en) * 1990-02-16 1992-06-23 Laboratoires Upsa Azabenzimidazole derivatives which are thromboxane receptor antagonists
WO1993005773A1 (fr) * 1991-09-24 1993-04-01 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Inhibition therapeutique de l'agregation plaquettaire par des complexes nucleophiles-oxyde nitrique et leurs derives
WO1999026933A1 (fr) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Derives d'amidinoaryle substitue et leur utilisation comme anticoagulants
WO1999026932A1 (fr) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Derives heterocycliques substitues par un groupe amidino et leur utilisation en tant qu'anticoagulants
WO1999040072A1 (fr) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques
WO2000001704A2 (fr) * 1998-07-04 2000-01-13 Boehringer Ingelheim Pharma Kg Benzimidazoles, leur preparation et leur utilisation comme medicaments
WO2000035886A2 (fr) * 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. Inhibiteurs de proteases
WO2001047572A2 (fr) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Dispositif et constituant actif destines a inhiber la formation de thrombus-matrice cellulaire inflammatoire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEM. ABSTR. (COLUMBUS, OHIO, USA); QU F. ET AL.: "Search for new antiphytovirucides. VIII. Phosphorylation, sulfonation and carboxymethylation of benzimidazole derivatives and antiviral activity of products", XP002960258, Database accession no. 1998:681864 *
DAVIS L.J. ET AL.: "Effect of oxaprozin on the steady-state anticoagulant activity of warfarin", CLIN. PHARM., vol. 3, no. 3, 1984, pages 295 - 297, XP002960260 *
EL-SHERIEF H.A. ET AL.: "Synthesis and antimicrobial activities of some new benzimidazoles. Part I", BULLETIN OF THE FACULTY OF SCIENCE, vol. 24, no. 1, 1995, pages 111 - 123, XP002960259 *
MEANWELL N.A.: "Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-(3-(2-(4,5-diphenyl-2-oxazolyl)ethyl)phenoxyacetic acid modified beta-to the oxazole ring", DRUG DESIGN AND DISCOVERY, vol. 11, no. 1, 1994, pages 73 - 89, XP002960261 *
NICOLAI E. ET AL.: "Synthesis and structure-activity relationships of novel benziidazole and imidazo(4,5-b)pyridine acid derivatives as thromboxane A2 receptor antagonists", J. MED. CHEM., vol. 36, no. 9, 1993, pages 1175 - 1187, XP002960257 *
WUHAN UNIV. J. NATURAL SCI., vol. 3, no. 2, 1998, pages 201 - 204 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530459A (ja) * 2004-03-26 2007-11-01 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP2007537253A (ja) * 2004-05-12 2007-12-20 アボット・ラボラトリーズ ３環式および２環式ヘテロアリールヒスタミン３受容体リガンド
JP4881859B2 (ja) * 2004-05-12 2012-02-22 アボット・ラボラトリーズ ３環式および２環式ヘテロアリールヒスタミン３受容体リガンド
WO2006023865A1 (fr) * 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
WO2007111136A1 (fr) * 2006-03-28 2007-10-04 Adeka Corporation Composition de resine epoxy durcissable
JP2007262204A (ja) * 2006-03-28 2007-10-11 Adeka Corp エポキシ樹脂硬化性組成物
US7763700B2 (en) 2006-03-28 2010-07-27 Adeka Corporation Epoxy resin curing composition
CN101389684B (zh) * 2006-03-28 2012-05-30 株式会社艾迪科 环氧树脂固化性组合物
WO2007138705A1 (fr) 2006-06-01 2007-12-06 Japan As Represented By Director General Of Agency Of National Cancer Center Suppresseur de tumeurs
US8323805B2 (en) 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
US8354668B2 (en) 2009-06-29 2013-01-15 Nitto Denko Corporation Emissive triaryls
US8927121B2 (en) 2009-06-29 2015-01-06 Nitto Denko Corporation Emissive aryl-heteroaryl compounds
US8426040B2 (en) 2010-12-22 2013-04-23 Nitto Denko Corporation Compounds for use in light-emitting devices
US9373797B2 (en) 2010-12-22 2016-06-21 Nitto Denko Corporation Compounds for use in light-emitting devices
US8933243B2 (en) 2011-06-22 2015-01-13 Nitto Denko Corporation Polyphenylene host compounds
US9548458B2 (en) 2011-06-22 2017-01-17 Nitto Denko Corporation Polyphenylene host compounds
CN105392777A (zh) * 2013-06-27 2016-03-09 株式会社Lg生命科学 作为gpr120激动剂的联芳基衍生物
US10221138B2 (en) 2013-06-27 2019-03-05 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
CN109456274A (zh) * 2018-12-07 2019-03-12 广东药科大学 苯并咪唑类衍生物、其制备方法及其作为药物的用途
CN109456274B (zh) * 2018-12-07 2021-11-05 广东药科大学 苯并咪唑类衍生物、其制备方法及其作为药物的用途

Also Published As

Publication number Publication date
JPWO2004010996A1 (ja) 2005-11-24
AU2002368133A1 (en) 2004-02-16
JP4334476B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
CN113292539B (zh) 取代的氧代吡啶衍生物
CN106854205B (zh) 流感病毒复制抑制剂及其使用方法和用途
CN106983751B (zh) 二环取代尿嘧啶及其用途
WO2004010996A1 (fr) Derive 1,3 azole et composition medicale contenant ce derive pour le traitement de thrombose
CN1794988B (zh) 用于治疗血管渗透性过高疾病的组合物
CN102239152B (zh) 新型酰胺衍生物及其作为药物的用途
KR20000010650A (ko) 피라지논 트롬빈 저해제
CN106008488B (zh) 氰基吲哚类衍生物及其制备方法和用途
CN102378753A (zh) 纤溶酶原激活物抑制因子-1抑制剂
TW201713642A (zh) １，４－二取代咪唑衍生物
CN102762101B (zh) 取代的稠合咪唑衍生物、药物组合物及其使用方法
CN108689942A (zh) 含氮双环化合物及其制备方法和用途
CN104334532A (zh) 异喹啉和二氮杂萘衍生物
CN105873919A (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN101541801A (zh) 稠杂环衍生物及其用途
JPH11510140A (ja) 金属タンパク質分解酵素阻害剤
JP4334508B2 (ja) １，３−アゾール誘導体
JP3966816B2 (ja) トロンボポエチン様活性を有する化合物
JP4390460B2 (ja) オキサゾール誘導体
BR112020022220A2 (pt) novo composto e composição farmacêutica compreendendo o mesmo
EP2022500A1 (fr) Suppresseur de tumeurs
JP4330353B2 (ja) ピリミジン誘導体
JP4556371B2 (ja) アシルスルホンアミド誘導体
KR20020000545A (ko) 폴리사이클릭 티아졸계 및 식욕 억제제로서의 이의 용도
JP3185700B2 (ja) ペプチジルアルデヒド誘導体およびその用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004524089

Country of ref document: JP

122 Ep: pct application non-entry in european phase